Maplight Therapeutics Says Phase 2 Zephyr Trial Of ML-007C-MA For Acute Exacerbation Of Schizophrenia Met Its Primary Endpoint, With 210/3 Mg Twice-Daily Dose, While 330/6 mg Once-daily Dose Missed Primary Endpoint
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with
Maplight's new schizophrenia medicine worked better than a placebo in a key test, but only with one dose size—the other dose didn't work as well. This is a step forward, though the company now needs to figure out which dose is best for patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.